Remdesivir.

Q1 Pharmacology, Toxicology and Pharmaceutics

Profiles of drug substances, excipients, and related methodology Pub Date : 2023-01-01 Epub Date: 2023-02-09 DOI:10.1016/bs.podrm.2022.11.003

Ahmed H Bakheit, Hany Darwish, Ibrahim A Darwish, Ahmed I Al-Ghusn

{"title":"Remdesivir.","authors":"Ahmed H Bakheit, Hany Darwish, Ibrahim A Darwish, Ahmed I Al-Ghusn","doi":"10.1016/bs.podrm.2022.11.003","DOIUrl":null,"url":null,"abstract":"<p><p>Remdesivir, marketed under the brand name Veklury, is an antiviral drug with a broad spectrum of activity. There were various countries where the use of Remdesivir for the treatment of COVID-19 was authorized during the pandemic. Remdesivir was first designed to treat hepatitis C, but it was later tested for Ebola virus sickness and Marburg virus infections. Remdesivir is a prodrug designed to facilitate the intracellular transport of GS-441524 monophosphate and its subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase. The objective of this chapter is to provide a comprehensive review of Remdesivir (GS-5734), including its nomenclature, physiochemical properties, preparation methods, identification procedures, numerous qualitative and quantitative analytical techniques, ADME profiles, and pharmacological effects. In addition, the chapter provides a variety of chromatographic and spectroscopic techniques for separating brimonidine from other drugs in combination formulations.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910426/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Profiles of drug substances, excipients, and related methodology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/bs.podrm.2022.11.003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/2/9 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Remdesivir, marketed under the brand name Veklury, is an antiviral drug with a broad spectrum of activity. There were various countries where the use of Remdesivir for the treatment of COVID-19 was authorized during the pandemic. Remdesivir was first designed to treat hepatitis C, but it was later tested for Ebola virus sickness and Marburg virus infections. Remdesivir is a prodrug designed to facilitate the intracellular transport of GS-441524 monophosphate and its subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase. The objective of this chapter is to provide a comprehensive review of Remdesivir (GS-5734), including its nomenclature, physiochemical properties, preparation methods, identification procedures, numerous qualitative and quantitative analytical techniques, ADME profiles, and pharmacological effects. In addition, the chapter provides a variety of chromatographic and spectroscopic techniques for separating brimonidine from other drugs in combination formulations.

Abstract Image

查看原文本刊更多论文

瑞德西韦

雷米地韦以 Veklury 品牌销售，是一种具有广泛活性的抗病毒药物。在 COVID-19 大流行期间，有多个国家批准使用 Remdesivir 治疗 COVID-19。Remdesivir 最初被设计用于治疗丙型肝炎，但后来对埃博拉病毒病和玛堡病毒感染进行了测试。雷米替韦是一种原药，旨在促进 GS-441524 单磷酸在细胞内的转运，并随后将其生物转化为 GS-441524 三磷酸，这是一种病毒 RNA 聚合酶的核糖核苷酸类似物抑制剂。本章旨在全面综述雷米替韦（GS-5734），包括其命名、理化性质、制备方法、鉴定程序、多种定性和定量分析技术、ADME 特征和药理作用。此外，本章还提供了多种色谱和光谱技术，用于在复方制剂中分离溴莫尼定和其他药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Profiles of drug substances, excipients, and related methodology Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

13.10

自引率

0.00%

发文量